MarginsXMarginsX
Home › Markets › Health Care › VALN

Valneva SE (VALN)

VALN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$5.65
-0.18% on the day
Market cap
$536.1M
Small cap
Revenue · 2025
$193.0M
+3.0% on 2024
Net income · 2025
-$127.3M
-66.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1836564/000162828026018808/0001628280-26-018808-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2025-12-31. Converted from EUR at 0.9048 per USD (today's ECB or Federal Reserve reference rate).

Profile

FieldValue
TickerVALN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryFrance
IPO year2021
SEC CIK0001836564
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inFrance

Financials · 2025

LineValue
Revenue$193.0M
Net income-$127.3M
Operating income-$90.7M
Net margin-66.0%
Operating margin-47.0%
Revenue growth+3.0%
Cash$121.2M
Total assets$440.8M
P/E (computed)Net income was not positive
P/S (computed)2.8×

Reported in EUR; shown in US dollars.

Warning signs

Cash runway
24.9 months
109.7M EUR cash at December 31, 2025
Share count, 1 year
+6.8%
2024-12-31 to 2025-12-31 · +25.4% over 3 years
Going-concern doubt
No
20-F filed March 17, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-03-17
Cash and burn109.7M EUR cash; operating cash flow -13.2M EUR a quarter.Report 2025-12-31
Shares outstanding86,769,873 (2025-12-31); 81,260,762 a year earlier; 69,183,741 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-06-04
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Associés, Paris-La Défense, FrancePCAOB Form AP 2026-04-16
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
174.7M EUR-115.2M EUR-52.9M EUR109.7M EUR179.2M EUR174.7M EUR20-F 2026-03-17
FY 2024
2024-12-31
169.6M EUR-12.2M EUR-67.2M EUR168.3M EUR187.4M EUR169.6M EUR20-F 2026-03-17
FY 2023
2023-12-31
153.7M EUR-101.4M EUR-202.7M EUR126.1M EUR176.8M EUR153.7M EUR20-F 2026-03-17
FY 2022
2022-12-31
361.3M EUR-143.3M EUR-245.3M EUR286.5M EUR98.8M EUR361.3M EUR20-F 2025-03-24
FY 2021
2021-12-31
348.1M EUR-61.4M EUR76.9M EUR346.7M EUR57.8M EUR348.1M EUR20-F 2024-03-22
FY 2020
2020-12-31
110.3M EUR-55.1M EUR137.7M EUR204.4M EUR53.4M EUR110.3M EUR20-F 2023-03-30
FY 2019
2019-12-31
126.2M EUR-811K EUR5.5M EUR64.4M EUR26.3M EUR126.2M EUR20-F 2022-03-24

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in EUR.

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS
424B32026-06-16
Latest annual report20-F2026-03-17
Latest quarterly / interim6-K2026-11-13

Source: SEC EDGAR submissions feed, 270 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.7%
1 month+1.8%
3 months+0.2%
Year to date-35.8%
1 year-38.7%
From 52-week high-52.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
ENTXEntera Bio Ltd.$3.02-2.89%$525.9M
ETRAElectra Therapeutics Inc.$8.31-6.00%$522.4M
DNAGinkgo Bioworks Holdings Inc.$8.50-11.55%$551.0M
IAMIambic Therapeutics Inc.$11.85-9.54%$561.7M
SANASana Biotechnology Inc.$1.88-6.93%$563.3M
RGNXREGENXBIO Inc.$7.32-4.19%$484.0M
SRZNSurrozen Inc.$32.32+2.25%$616.1M
CGEMCullinan Therapeutics Inc.$9.50-7.59%$616.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier